{"id":9120,"date":"2020-04-17T19:02:13","date_gmt":"2020-04-17T13:32:13","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9120"},"modified":"2025-05-08T13:45:52","modified_gmt":"2025-05-08T08:15:52","slug":"car-t-cell-therapy-market-for-non-hodgkin-lymphoma","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma","title":{"rendered":"CAR-T cell therapy market for Non-Hodgkin lymphoma: Future prospects, and untapped opportunities"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a1d5ecfec784\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a1d5ecfec784\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma\/#CAR-T_cell_therapy_market_for_lymphomas\" >CAR-T cell therapy market for lymphomas&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma\/#CAR-T_cell_therapy_market_for_Non-Hodgkin_Lymphoma\" >CAR-T cell therapy market for Non-Hodgkin Lymphoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma\/#CAR-T_cell_therapy_market_Emerging_therapies_and_growing_size\" >CAR-T cell therapy market: Emerging therapies and growing size&nbsp;&nbsp;<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma\/#Drivers_and_Barriers\" >Drivers and Barriers&nbsp;<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n<p><em>As per DelveInsight, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-non-hodgkins-lymphoma-market\">CAR T-Cell Therapy Market size for Non-Hodgkin lymphoma<\/a> in the 6MM (the US, EU5 (the UK, Germany, France, Italy and Spain)) is expected to be <\/em><strong><em>USD 2796.2 Million by 2030<\/em><\/strong><em>.<\/em><\/p>\n\n\n\n<p>During the course of past decades, with the advancement in technology and a clear understanding of the molecular pathogenesis, cellular processes that take place during lymphomagenesis such as signal transduction pathways, transcriptional and translational regulation, protein stability and degradation, cell cycle regulation, and mitosis and apoptosis, as well as the study of the microenvironment, a significant number of effective treatments have graced the Non-Hodgkin lymphoma therapeutics market, improving the quality of lives of the patients, increasing survival rates, and life expectancies of the patients.&nbsp;<\/p>\n\n\n\n<p>Ultimately, it has led to an increase in the discovery and progress of new therapies with a considerable number of breakthrough molecules quite impressively managed to influence the Non-Hodgkin lymphoma treatment landscape.<\/p>\n\n\n\n<p>Chemotherapies, radiation therapies and immunotherapies are either used in combination or alone, depending upon the severity, success rate, age and several other factors. Immunotherapies such as BCR pathway inhibitors including Bruton&#8217;s tyrosine kinase (BTK) inhibitors, spleen tyrosine kinase (Syk) inhibitors, and phosphatidyl-inositol-3-kinase (PI3K) inhibitors; Bcl-2 inhibitors comprising are such agents that proved to be effective to some extent in treating Non-Hodgkin lymphoma. However, the emergence of new generation monoclonal antibodies (mAbs) and drug conjugates such as Obinutuzumab were even more effective when used with chemotherapy have complemented the existing conventional therapies. Chemotherapy is one of the most conventional methods to treat patients, and most patients are given cytotoxic chemotherapy in combination with the anti-CD20 monoclonal antibody Rituximab (Rituxan) for successful removal of tumor.<\/p>\n\n\n\n<p>However, the treatment approach has its limitations, and the results are never 100% depicting a conflicting side of the story. The patients develop progressive tumors, and there were cases when the cancer relapsed or recurred. Hence, the dire need to shift the complete reliance of patients from such conventional therapies to a novel approach that can treat cancer for once and all.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CAR-T_cell_therapy_market_for_lymphomas\"><\/span><strong>CAR-T cell therapy market for lymphomas&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A branch of immunotherapy has recently caught attention involves the transfer of patient&#8217;s own immune cells to target the cancerous cells \u2013 known adoptive cell transfer (ACT). However, it is of several types, but one that received much attention is <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market\">CAR-T cell therapy<\/a>.&nbsp;<\/p>\n\n\n\n<p>Until recently, CAR-T cell therapy was confined to clinical trials on smaller scales, in patients who opted for it as a last resort. However, the remarkable rates of success garnered much attention from researchers, investors and patients equally.&nbsp;<\/p>\n\n\n\n<p>The therapy proved to be a miracle for cancer patients \u2013 regardless of their ages \u2013 for whom results of every treatment approach looked nothing but grim.&nbsp;<\/p>\n\n\n\n<p>As the name goes, <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-multiple-myeloma-market\">CAR-T cell therapy<\/a> relies on T-cells \u2013 workhorses of immune cells -which are extracted from patient, cultured, and genetically engineered to bear receptors on their cells \u2013 Chimeric antigen receptors (CARs). These genetically engineered T-cells bind to cancerous cells, hence killing them.&nbsp;<\/p>\n\n\n\n<p>The available therapeutics treatment options in <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-non-hodgkins-lymphoma-market\">CAR T-Cell Therapy market for Non-Hodgkin lymphoma<\/a> aim to kill the <a href=\"https:\/\/www.delveinsight.com\/report-store\/adult-t-cell-leukemia-lymphoma-market\">leukemia <\/a>cells in the blood and bone marrow. The approval of Yescarta was proved to be the light of the day for the group of cancer patients who were left with a few other options, and those with certain types of <a href=\"https:\/\/www.delveinsight.com\/report-store\/b-cell-non-hodgkin-lymphoma-market\">lymphoma <\/a>that had not responded to previous treatments.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CAR-T_cell_therapy_market_for_Non-Hodgkin_Lymphoma\"><\/span><strong>CAR-T cell therapy market for Non-Hodgkin Lymphoma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>While opting for <strong>Yescarta<\/strong>, the patient&#8217;s T-cells are modified ex-vivo to generate a CAR consisting of anti-CD19 CAR T-cells linked to CD28 and CD3-zeta co-stimulatory domains. These anti-CD19 CAR T-cells are then transferred back to the patient, which recognizes CD-19 expressing target cells, eliminating it. The tussle between anti-CD19 CAR T-cells and CD19-expressing target cells leads to the activation of downstream signals, which further result in the activation of T-cells, proliferation, and release of inflammatory cytokines, as well as killing CD19-expressing cells.<\/p>\n\n\n\n<p>Effectiveness of the CAR-T cell therapy has led scientists and researchers to ponder over its use in cancer patients at earlier stages. Nonetheless, it still requires extensive research and studies which are underway, comparing the results of the patients given CAR-T at different stages.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CAR-T_cell_therapy_market_Emerging_therapies_and_growing_size\"><\/span><strong>CAR-T cell therapy market: Emerging therapies and growing size&nbsp;&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The approval of the novel CAR-T cell therapy attracted many pharma investors and pharma companies, highlighting the bright scope of CAR-T cell therapies in oncology.&nbsp;<\/p>\n\n\n\n<p>Several companies, including Celgene, and Gilead, are working to fuel the <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-non-hodgkins-lymphoma-market\">CAR-T cell therapy market for Non-Hodgkin lymphoma<\/a>. The expected launch of <strong>Lisocabtagene maraleucel<\/strong> (also known as JCAR017) of Celgene&#8217;s, (a BMS company) and <strong>KTE-X19 <\/strong>by Gilead will significantly drive the NHL market in the near future.<\/p>\n\n\n\n<p>Gilead&#8217;s KTE-X19, an investigational CD19 CAR T-cell therapy, has been granted fast-track review designation by the FDA for cellular drug therapy to treat a rare form of non-Hodgkin lymphoma. Moreover, KTE-X19 is currently in Phase I\/II trials in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). Similarly, Celgene&#8217;s JCAR017 (Lisocabtagene maraleucel), is in phase I stage of development for the treatment of pediatric Acute Lymphoblastic Leukemia and adult Non-Hodgkin Lymphoma.<\/p>\n\n\n\n<p class=\"has-text-color has-background has-vivid-red-color has-very-light-gray-background-color\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-non-hodgkins-lymphoma-market\"><strong>As per DelveInsight, the CAR T-Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM (the US, EU5 (the UK, Germany, France, Italy and Spain)) is expected to be USD 2796.2 Million by 2030.<\/strong><\/a> <\/p>\n\n\n\n<p>Among the EU-5 countries, Germany, Italy and France are observed to be among top holders of the largest CAR T-Cell Therapy market share for Non-Hodgkin lymphoma followed by UK and Spain.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Drivers_and_Barriers\"><\/span><strong>Drivers and Barriers&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The major market driver in the<a href=\"https:\/\/www.delveinsight.com\/blog\/non-hodgkins-lymphoma-nhl-market-insights-epidemiology-and-market-forecast-2020\/\"> CAR T-Cell Therapy market for NHL<\/a> is the launch of the anticipated gene therapies. The surge in the CAR-T cell therapy market size would automatically mean a decline in the market share of the current therapies present in the Non-Hodgkin lymphoma market. Developing such advanced CAR-T cell therapies is complex and is faced with several challenges. However, with two approved CAR-T cell therapies (Kymriah, Novartis; Yescarta, Kite Pharma) available in the market for different types of lymphomas, regulatory bodies have enhanced their support by easing out the regulations such as FDA&#8217;s breakthrough designations, and orphan designations; and EMA&#8217;s PRIority MEdicines (PRIME) scheme to make available CAR-T cell therapies in the market. Regulatory authorities have started to consider the results on the basis of small-scale trials and smaller databases. However, every story has two sides. CAR-T cell therapy is met with significant challenges related to its cost and affordability. Curative, and life-changing gene therapies, for sure have graced our lives, promising a cancer-free life, however; at a hefty amount. <\/p>\n\n\n\n<p>However, EMA-HTA Parallel Consultation and other schemes help to discuss and agree on approving a reimbursement plan that assesses risk and values, maintaining a balance. Moreover, an early plan among medicines developers, regulators, health technology assessment bodies, and health care insurers benefits the patients to get a clear understanding of the reimbursement procedure.&nbsp;With two CAR-T cell therapies available, might have transitioned to next level, however; several challenges await, which pharma companies and academia through their collaboration and partnership are trying to overcome to fuel the <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-non-hodgkins-lymphoma-market\">CAR-T cell therapy market for Non-Hodgkin lymphoma<\/a>.  <\/p>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1587123986888\"><strong class=\"schema-faq-question\"><strong>What is the future of the CAR T-Cell Therapy Market size for Non-Hodgkin lymphoma<\/strong>?\u00a0<\/strong> <p class=\"schema-faq-answer\">As per DelveInsight, the CAR T-Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM is expected to be USD 2796.2 Million by 2030.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1587124056553\"><strong class=\"schema-faq-question\"> <strong>What are the major market drivers in the CAR T-Cell Therapy market for NHL<\/strong>?<\/strong> <p class=\"schema-faq-answer\"> The major market driver in the CAR T-Cell Therapy market for NHL is the launch of the anticipated gene therapies, including Lisocabtagene maraleucel of Celgene&#8217;s, (a BMS company) and KTE-X19 by Gilead.\u00a0<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1587124085187\"><strong class=\"schema-faq-question\"> <strong>What are the major market barriers in the CAR T-Cell Therapy market for NHL<\/strong>?<\/strong> <p class=\"schema-faq-answer\"> The major market barriers in the CAR T-Cell Therapy market for NHL are complexity of tissue engineering, different regulatory guidelines, and attached price tag.\u00a0 <\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1587124096672\"><strong class=\"schema-faq-question\"> <strong>What are the major companies working in CAR-T cell therapy market for NHL<\/strong>?\u00a0<\/strong> <p class=\"schema-faq-answer\"> Several companies are working to fuel the CAR-T cell therapy market for NHL, including Celgene \u2013 a BMS subsidiary, Gilead, and others.\u00a0<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>As per DelveInsight, the CAR T-Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM (the US, EU5 (the UK, Germany, France, Italy and Spain)) is expected to be USD 2796.2 Million by 2030. During the course of past decades, with the advancement in technology and a clear understanding of the molecular pathogenesis, cellular processes [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9138,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[18240,1976,810,12288,12289,141,2675,18239,12287,2831],"industry":[17225],"therapeutic_areas":[17235],"class_list":["post-9120","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-car-t-cell-therapy-market-for-non-hodgkin-lymphoma","tag-car-t-cell-therapy","tag-car-t","tag-car-t-cell-therapy-market","tag-car-t-cell-therapy-market-non-hodgkin-lymphoma","tag-car-t-therapy-landscape","tag-cell-therapy","tag-lisocabtagene-maraleucel","tag-lymphomas","tag-non-hodgkin-lymphoma","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CAR-T cell therapy market for Non-Hodgkin lymphoma (NHL)<\/title>\n<meta name=\"description\" content=\"As per DelveInsight, the CAR-T Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM is expected to be USD 2796.2 Million by 2030.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAR-T cell therapy market for Non-Hodgkin lymphoma (NHL)\" \/>\n<meta property=\"og:description\" content=\"As per DelveInsight, the CAR-T Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM is expected to be USD 2796.2 Million by 2030.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-17T13:32:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T08:15:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/17185629\/Car-t-cell-NHL.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CAR-T cell therapy market for Non-Hodgkin lymphoma (NHL)","description":"As per DelveInsight, the CAR-T Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM is expected to be USD 2796.2 Million by 2030.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma","og_locale":"en_US","og_type":"article","og_title":"CAR-T cell therapy market for Non-Hodgkin lymphoma (NHL)","og_description":"As per DelveInsight, the CAR-T Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM is expected to be USD 2796.2 Million by 2030.","og_url":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-04-17T13:32:13+00:00","article_modified_time":"2025-05-08T08:15:52+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/17185629\/Car-t-cell-NHL.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma","url":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma","name":"CAR-T cell therapy market for Non-Hodgkin lymphoma (NHL)","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/17185629\/Car-t-cell-NHL.jpg","datePublished":"2020-04-17T13:32:13+00:00","dateModified":"2025-05-08T08:15:52+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"As per DelveInsight, the CAR-T Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM is expected to be USD 2796.2 Million by 2030.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma#faq-question-1587123986888"},{"@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma#faq-question-1587124056553"},{"@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma#faq-question-1587124085187"},{"@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma#faq-question-1587124096672"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/17185629\/Car-t-cell-NHL.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/17185629\/Car-t-cell-NHL.jpg","width":772,"height":482,"caption":"CAR-T cell therapy market for Non-Hodgkin lymphoma"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma#faq-question-1587123986888","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma#faq-question-1587123986888","name":"What is the future of the CAR T-Cell Therapy Market size for Non-Hodgkin lymphoma?\u00a0","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"As per DelveInsight, the CAR T-Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM is expected to be USD 2796.2 Million by 2030.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma#faq-question-1587124056553","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma#faq-question-1587124056553","name":"What are the major market drivers in the CAR T-Cell Therapy market for NHL?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":" The major market driver in the CAR T-Cell Therapy market for NHL is the launch of the anticipated gene therapies, including Lisocabtagene maraleucel of Celgene's, (a BMS company) and KTE-X19 by Gilead.\u00a0","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma#faq-question-1587124085187","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma#faq-question-1587124085187","name":"What are the major market barriers in the CAR T-Cell Therapy market for NHL?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":" The major market barriers in the CAR T-Cell Therapy market for NHL are complexity of tissue engineering, different regulatory guidelines, and attached price tag.\u00a0 ","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma#faq-question-1587124096672","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-for-non-hodgkin-lymphoma#faq-question-1587124096672","name":"What are the major companies working in CAR-T cell therapy market for NHL?\u00a0","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":" Several companies are working to fuel the CAR-T cell therapy market for NHL, including Celgene \u2013 a BMS subsidiary, Gilead, and others.\u00a0","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/17185629\/Car-t-cell-NHL-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">CAR T Cell Therapy Market For Non-Hodgkin Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">CAR T-cell Therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">CAR-T<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">CAR-T cell therapy market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">CAR-T cell therapy market - Non-Hodgkin Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">CAR-T Therapy Landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">cell therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Lisocabtagene Maraleucel<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">lymphomas<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Non-Hodgkin lymphoma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">CAR T Cell Therapy Market For Non-Hodgkin Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">CAR T-cell Therapy<\/span>","<span class=\"advgb-post-tax-term\">CAR-T<\/span>","<span class=\"advgb-post-tax-term\">CAR-T cell therapy market<\/span>","<span class=\"advgb-post-tax-term\">CAR-T cell therapy market - Non-Hodgkin Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">CAR-T Therapy Landscape<\/span>","<span class=\"advgb-post-tax-term\">cell therapy<\/span>","<span class=\"advgb-post-tax-term\">Lisocabtagene Maraleucel<\/span>","<span class=\"advgb-post-tax-term\">lymphomas<\/span>","<span class=\"advgb-post-tax-term\">Non-Hodgkin lymphoma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Apr 17, 2020","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on Apr 17, 2020 7:02 pm","modified":"Updated on May 8, 2025 1:45 pm"},"featured_img_caption":"CAR-T cell therapy market for Non-Hodgkin lymphoma","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9120"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9120\/revisions"}],"predecessor-version":[{"id":31974,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9120\/revisions\/31974"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9138"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9120"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9120"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}